|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of products sold | |||||
| Gross profit | |||||
| Selling expenses | |||||
| General and administrative expenses | |||||
| Research and development expenses | |||||
| Net gain on sales of businesses | |||||
| Loss on impairment of goodwill | |||||
| Amortization of intangibles | |||||
| Income from operations | |||||
| Interest and debt expense | |||||
| Cost of debt refinancing | |||||
| Investment (income) loss, net | |||||
| Foreign currency exchange loss (gain), net | |||||
| Other (income) expense, net | |||||
| Income (Loss) before income tax expense | |||||
| Income tax (benefit) expense | |||||
| Net income (loss) | |||||
| Net loss attributable to noncontrolling interest | |||||
| Net income (loss) attributable to the Company | |||||
| Average basic shares outstanding (in shares) | |||||
| Average diluted shares outstanding (in shares) | |||||
| Basic income (loss) per common share (in dollars per share) | |||||
| Diluted income (loss) per common share (in dollars per share) | |||||
| Dividends declared per common share (in dollars per share) | |||||
Loading...